Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response.

Next Previous
Trial Profile

Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Post-traumatic stress disorders; Traumatic brain injuries
  • Focus Therapeutic Use

Most Recent Events

  • 01 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2026.
  • 01 Mar 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Mar 2026.
  • 27 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top